“It’s one thing to invent a machine that prints skin, but it’s a whole other challenge to bring what seems like the domain of mad science to mass production,” Matthew Braga wrote in "Looking for ways to get 'skin' in the game," published in the Financial Post on July 15.
The article focuses on MaRS Innovation's (MI) and the Innovations and Partnerships Office's (University of Toronto) joint efforts to commercialize the bio printer, a "prototype 3D printer that, instead of extruding layers ...
MI's Fanny Sie and Shotlst Co-founder Matt Ratto talk bioprinting, healthcare, civil rights and home manufacturing with Steve Paikin
Fanny Sie, project manager in physical sciences and medical devices with specialization in medical imaging, appeared on TVO’s The Agenda on June 5, 2013 to discuss 3D printing.
Click here to watch Fanny Sie on The Agenda.
Sie manages the Bioprinter technology, which was touched upon during the interview. The bioprinter was invented by Axel Guenther, a professor in the University of Toronto’s Department of Mechanical ...
MaRS Innovation's Fanny Sie, project manager in physical sciences and medical devices with specialization in medical imaging, is appearing on TVO's The Agenda with Steve Paikin at 8 pm on June 5, 2013 to discuss 3D printing and the technology's applications in healthcare and other aspects of human society.
Sie manages the Bioprinter technology, which was invented by Axel Guenther, a professor in the University of Toronto’s Department of Mechanical and Industrial Engineering, PhD student Lian Leng and a team of other researchers. ...
Four University of Toronto (U of T) professors who have commercialization projects in various stages with MaRS Innovation were named to the university's list of Inventors of the Year.
“The Inventor of the Year Award is meant to recognize inventions that have the potential to improve our quality of life,” said Professor Paul Young, vice-president (research and innovation) and a member of MaRS Innovation's Board of Directors. “The winning inventions represent the very best of innovation at U of T, and on ...
Dana Fox, vice chair of Waterloo-based ClevrU Corporation, was featured in CBC's Transforming Tech: Changing Careers in the Digital Age series, hosted by Matthew Kang.
The interview explores Fox's career and decision to co-found ClevrU and his ongoing role in the start-up's development.
Fox's interview runs just over six minutes. After clicking the link, scroll down the page to the second interview to play the audio file.
TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics.
Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.
“There’s growing consensus that transferring technologies from the university lab ...
A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada
CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector.
Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for ...
Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada.
The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program.
This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012.
The initial consideration of $1.6 million for the UHN ...